临床肝胆病杂志2017，Vol.33Issue(7)：1270-1273,4.DOI:10.3969/j.issn.1001-5256.2017.07.013
肝炎病毒相关性肝细胞癌的抗病毒治疗现状与挑战
Antiviral therapy for hepatitis virus-related hepatocellular carcinoma: current status and challenges
董菁 1江家骥1
作者信息
- 1. 福建医科大学附属第一医院 肝病中心,福州 350001
- 折叠
摘要
Abstract
The incidence rate of hepatocellular carcinoma (HCC) is increasing around the world and tends to decrease in East Asia and several regions in China;however, China still has higher incidence rate and mortality rate of HCC than most countries.Studies have shown that long-term antiviral therapy can inhibit HBV replication to a very low level or help patients with HCV infection achieve sustained virologic response, which can further reduce the incidence rate of virus-related HCC.New evidence suggests that compared with nucleos(t)ide analogues, PEG-IFNα has a better effect of secondary prevention.Studies also indicate that interferons play an important role in tertiary prevention of virus-related HCC.This article reviews the epidemiological studies on virus-related HCC in recent years and the role of antiviral therapy in second and tertiary prevention and points out that adequate and effective antiviral therapy is the basis for preventing the development and recurrence of HCC.关键词
癌,肝细胞/肝炎病毒/抗病毒药/治疗Key words
carcinoma,hepatocellular/hepatitis viruses/antiviral agents/therapy分类
医药卫生引用本文复制引用
董菁,江家骥..肝炎病毒相关性肝细胞癌的抗病毒治疗现状与挑战[J].临床肝胆病杂志,2017,33(7):1270-1273,4.
